123_CD
Alliance_NN
UniChem_NN
Plc_NN
N_NN
PRINCIPAL_NN
SUBSIDIARY_NN
UNDERTAKINGS_GER
The_DT
principal_JJ
subsidiary_NN
undertakings_GER
of_PIN
Alliance_NN
UniChem_NN
Plc_NN
,_,
all_QUAN
of_PIN
which_WDT [PIRE]
were_VBD [SPAU] [PASS]
indirectly_RB
held_VBN [PRIV]
,_,
were_VBD
:_:
Interest_NN
in_PIN
ordinary_JJ
share_NN
capital_NN
and_PHC
Country_NN
of_PIN
Country_NN
of_PIN
voting_NN
rights_NN
operation_NOMZ
incorporation_NOMZ
Main_NN
activity_NOMZ
Northern_NN
Europe_NN
Wholesale_JJ
UniChem_NN
Limited_NN
100_CD
%_NN
UK_NN
UK_NN
pharmaceutical_JJ
wholesaler_NN
Interpharm_NN
B._NN
V._NN
100_CD
%_NN
The_DT
Netherlands_NN
The_DT
Netherlands_NN
pharmaceutical_JJ
wholesaler_NN
Alliance_NN
UniChem_NN
CZ_NN
Spo_NN
97.1_CD
%_NN
Czech_JJ
Republic_NN
Czech_JJ
Republic_NN
pharmaceutical_JJ
wholesaler_NN
Holtung_NN
A._NN
S._NN
100_CD
%_NN
Norway_NN
Norway_NN
pharmaceutical_JJ
wholesaler_NN
Southern_NN
Europe_NN
Wholesale_JJ
Alliance_NN
Sant_NN
S._NN
A._NN
99.8_CD
%_NN
France_NN
France_NN
pharmaceutical_JJ
wholesaler_NN
Alleanza_NN
Salute_NN
Italia_NN
SpA_NN
100_CD
%_NN
Italy_NN
Italy_NN
pharmaceutical_JJ
wholesaler_NN
and_CC
holding_VBG [PRIV]
company_NN
Safa_NN
Galenica_NN
S._NN
A._NN
99.2_CD
%_NN
Spain_NN
Spain_NN
pharmaceutical_JJ
wholesaler_NN
Alloga_NN
S._NN
A._NN
100_CD
%_NN
Europe_NN
Luxembourg_NN
holding_VBG [PRIV] [WZPRES]
company_NN
for_PIN
a_DT
number_NN
of_PIN
pre-wholesalers_NN
Retail_NN
E._NN
Moss_NN
Limited_NN
100_CD
%_NN
UK_NN
UK_NN
retail_JJ
pharmacy_NN
operator_NN
Alliance_NN
UniChem_NN
Norge_NN
A._NN
S._NN
100_CD
%_NN
Norway_NN
Norway_NN
retail_JJ
pharmacy_NN
operator_NN
fide_NN
Vier_NN
Vijzels_NN
B._NN
V._NN
100_CD
%_NN
The_DT
Netherlands_NN
The_DT
Netherlands_NN
retail_JJ
pharmacy_NN
operator_NN
As_IN
permitted_VBN
by_PIN
section_NOMZ
231_CD
5_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
,_,
only_DWNT
principal_JJ
undertakings_GER
are_VPRT [PASS]
shown_VBN [PRIV]
._.
A_DT
complete_JJ
list_NN
of_PIN
all_QUAN
subsidiary_NN
undertakings_GER
is_VPRT [PASS]
filed_VBN
with_PIN
the_DT
Companys_NN
annual_JJ
return_NN
._.
O_NN
PRINCIPAL_NN
ASSOCIATED_VBD
UNDERTAKINGS_GER
The_DT
principal_NN
associated_VBN
undertakings_GER
of_PIN
Alliance_NN
UniChem_NN
Plc_NN
are_VPRT [PASS]
set_VBN
out_PIN
in_PIN
the_DT
table_NN
below_PLACE
._.
Except_PIN
for_PIN
25_CD
%_NN
of_PIN
the_DT
interest_NN
in_PIN
Hedef_NN
Alliance_NN
Holding_GER
A._NN
S._NN
these_DEMP
were_VBD [SPAU] [PASS]
indirectly_RB
held_VBN [PRIV]
._.
Interest_NN
in_PIN
ordinary_JJ
share_NN
capital_NN
and_PHC
Country_NN
of_PIN
Country_NN
of_PIN
voting_NN
rights_NN
operation_NOMZ
incorporation_NOMZ
Main_NN
activity_NOMZ
1_CD
Alliance_NN
UniChem_NN
Farmacutica_NN
S._NN
A._NN
49_CD
%_NN
Portugal_NN
Portugal_NN
pharmaceutical_JJ
wholesaler_NN
Andreae-Noris_NN
Zahn_NN
AG_NN
29.99_CD
%_NN
Germany_NN
Germany_NN
pharmaceutical_JJ
wholesaler_NN
2_CD
Galenica_NN
A._NN
G._NN
25.5_CD
%_NN
Switzerland_NN
Switzerland_NN
pharmaceutical_JJ
wholesaler_NN
Hedef_NN
Alliance_NN
Holding_GER
A._NN
S._NN
50_CD
%_NN
Turkey_NN
Turkey_NN
pharmaceutical_JJ
wholesaler_NN
Pharmapartners_NN
B._NN
V._NN
40_CD
%_NN
The_DT
Netherlands_NN
The_DT
Netherlands_NN
pharmaceutical_JJ
software_NN
UniDrug_NN
Distribution_NOMZ
Group_NN
Limited_NN
50_CD
%_NN
United_NN
Kingdom_NN
United_NN
Kingdom_NN
pre-wholesaler_JJ
Unifarma_NN
Distribuzione_NN
S._NN
r._NN
l._VBD
36_CD
%_NN
Italy_NN
Italy_NN
pharmaceutical_JJ
wholesaler_NN
1_CD
The_NN
Group_NN
previously_TIME
owned_VBD
100_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
Alliance_NN
UniChem_NN
Farmacutica_NN
S._NN
A._NN
._.
51_CD
%_NN
of_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
was_VBD [PASS]
disposed_VBN
of_PIN
during_PIN
the_DT
year_NN
._.
2_CD
All_QUAN
shares_NN
have_VPRT
the_DT
same_JJ
voting_NN
rights_NN
,_,
but_CC
no_SYNE
shareholder_NN
may_POMD
exercise_VB
more_EMPH
than_PIN
20_CD
%_NN
of_PIN
the_DT
votes_NN
._.
P_NN
CONTINGENT_NN
LIABILITIES_NOMZ
The_NN
Group_NN
offers_VPRT
its_PIT
UK_NN
wholesale_JJ
customers_NN
access_NN
to_PIN
long_JJ
term_NN
financing_GER
for_PIN
their_TPP3
pharmacy_NN
businesses_NOMZ
through_PIN
financing_VBG
arrangements_NOMZ
developed_VBN [WZPAST]
by_PIN
the_DT
Group_NN
with_PIN
its_PIT
banks_NN
._.
The_DT
Company_NN
supports_VPRT
these_DEMO
arrangements_NOMZ
through_PIN
the_DT
provision_NN
of_PIN
guarantees_NN
,_,
which_WDT [SERE]
at_PIN
31_CD
December_NN
2005_CD
amounted_VBD
to_PIN
19.6_CD
million_CD
2004_CD
18.6_CD
million_CD
._.
